eligibility_summary
Eligible: 15-75 yrs with relapsed/refractory B-cell lymphoma, ECOG 0-2, >=3-mo survival, CD20+, CD19 CAR-T tolerant or low CD19, no serious heart/lung/liver/kidney disease, apheresis-eligible, measurable disease, prior standard 1st/2nd-line, no antibody drugs <=2 wks. Exclude: allergy, severe cytopenias/organ dysfunction, major cardiac/resp/neuro disease, autoimmunity/immunosuppression, active infection, prior CAR-T/GM T, live vaccine <4 wks, HIV/HBV/HCV/syphilis, substance/mental illness, other trial <3 mo, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Autologous, gene‑modified CAR‑T cells—either dual‑target CD19/CD20-CAR.p40-T or CD19-CAR.p40-T—given after fludarabine + cyclophosphamide lymphodepletion. Type: adoptive cellular immunotherapy (genetically engineered T cells), FC are cytotoxic chemotherapies (purine analog and alkylator). Mechanisms of action: CARs bind CD19 and/or CD20 on B‑cell lymphomas, triggering T‑cell activation and cytolytic killing, an autocrine p40 cytokine module is included to enhance CAR‑T activation, expansion, and persistence, lymphodepletion reduces endogenous lymphocytes to improve CAR‑T engraftment. Targets (cells/pathways): malignant B cells expressing CD19 and CD20, T‑cell activation via CAR signaling, cytokine signaling modulated by p40, host lymphocyte/DNA synthesis pathways targeted by FC.